Foundayo (Orforglipron) Side Effects
Foundayo (orforglipron) side effects: GI effects from the ATTAIN trials, label warnings, and how they compare with other GLP-1s. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Foundayo is orforglipron, a once-daily non-peptide GLP-1 pill approved by the FDA in 2026 for weight management. In the phase 3 ATTAIN trials the most common side effects were gastrointestinal — nausea, constipation, diarrhoea, vomiting and indigestion — mostly mild to moderate and most frequent during dose escalation; some participants stopped treatment because of them. The label carries GLP-1 class warnings such as pancreatitis, gallbladder problems and dehydration-related kidney injury. This site has no tagged Foundayo confessions yet; the closest reports are semaglutide and tirzepatide. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
What users report here
Anonymous accounts are collected on the Semaglutide reports. They are personal stories, often with other compounds in the mix, not evidence of effect.
related peptides:
community guides:
More confessions from the archive
Community Q&A
- What are the most common Foundayo side effects?
- Nausea, constipation, diarrhoea, vomiting and indigestion, mostly early in treatment.
- Is Foundayo easier on the stomach than injections?
- Trials showed a similar GI side-effect class. There is no head-to-head tolerability result against injectables.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.